Brief: Evotec And Odyssey Therapeutics Enter AI-Enabled R&D Collaboration In Autoimmune And Inflammatory Diseases
06/08/2026 06:44
BRIEF-Evotec And Odyssey Therapeutics Enter AI-Enabled R&D Collaboration In Autoimmune And Inflammatory Diseases Aug 6 (Reuters) - Evotec SE EVTG.DE:
EQS-NEWS: EVOTEC AND ODYSSEY THERAPEUTICS ENTER AI-ENABLED RESEARCH AND DEVELOPMENT COLLABORATION IN AUTOIMMUNE AND INFLAMMATORY DISEASES
EVOTEC SE - ELIGIBLE FOR MILESTONE PAYMENTS UNDER COLLABORATION; FINANCIAL TERMS NOT DISCLOSED
EVOTEC SE - TO DELIVER VALIDATED HIT SERIES FOR MULTIPLE INFLAMMATORY AND AUTOIMMUNE DISEASE TARGETS
Source text: ID:nEQ7FR85za
Further company coverage: EVTG.DE
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Evotec SE
See all newsEvotec up 7% in early trade after 9-month revenue, earnings beat
Brief: Evotec Says Preliminary Nine-Month 2026 Results Above Market Expectations
Brief: Evotec Initiates Phase 1 Trial For Jst-018 Antibodies Targeting Orthopoxviruses
Brief: EVOTEC Q2 Group Revenues €143.50 Mln
Brief: Evotec And Odyssey Therapeutics Enter AI-Enabled R&D Collaboration In Autoimmune And Inflammatory Diseases